STOCK TITAN

Repligen (RGEN) director Margaret Pax receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corp director Margaret Pax reported equity awards consisting of restricted stock units and stock options. She was granted 995 restricted stock units, each representing one future share of common stock, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting. She also received options for 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036, with the award vesting on the same schedule. Following the grant, she directly holds 3,011 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Pax Margaret
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,239 $0.00 --
Grant/Award Common Stock 995 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,239 shares (Direct, null); Common Stock — 3,011 shares (Direct, null)
Footnotes (1)
  1. Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Restricted stock units granted 995 units Award to director Margaret Pax on May 14, 2026
Stock options granted 2,239 options Award to purchase Repligen common stock
Option exercise price $103.38 per share Stock option grant dated May 14, 2026
Option expiration date May 14, 2036 End of exercise period for 2,239 options
Shares held after transaction 3,011 shares Common stock directly owned by Margaret Pax
Vesting date trigger May 14, 2027 Earlier of this date or next annual meeting
restricted stock units financial
"Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"Stock Option (Right to Buy)... Award vests in full on the earlier of May 14, 2027..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "103.3800" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of the Company's shareholders financial
"or the date of the next annual meeting of the Company's shareholders, which has not yet been determined."
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pax Margaret

(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100

(Street)
WALTHAM MASSACHUSETTS 02453

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026A995(1)A$0.003,011D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$103.3805/14/2026A2,23905/14/2027(2)05/14/2036Common Stock2,239$0.002,239D
Explanation of Responses:
1. Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
/s/ Jennifer Carmichael (Attorney in Fact)05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Repligen (RGEN) director Margaret Pax report?

Margaret Pax reported receiving equity compensation awards, not open-market trades. She was granted 995 restricted stock units and stock options for 2,239 shares of Repligen common stock, both vesting on a future schedule tied to May 14, 2027 or the next annual shareholder meeting.

How many restricted stock units did Margaret Pax receive from Repligen (RGEN)?

She received 995 restricted stock units. Each unit represents a contingent right to one Repligen common share, vesting on the earlier of May 14, 2027, one year from grant, or the date of the next annual meeting of shareholders, whichever occurs first according to the award terms.

What are the key terms of Margaret Pax’s stock options in Repligen (RGEN)?

She was granted stock options covering 2,239 shares of Repligen common stock at an exercise price of $103.38 per share. The options vest in full on the earlier of May 14, 2027 or the next annual shareholder meeting and expire on May 14, 2036 if not exercised.

Did Margaret Pax buy or sell Repligen (RGEN) shares in the market?

She did not buy or sell shares in the open market. The Form 4 reflects equity compensation grants: 995 restricted stock units and options for 2,239 shares, both awarded at zero purchase price as part of her role as a director, with future vesting conditions attached.

How many Repligen (RGEN) shares does Margaret Pax hold after these awards?

After the reported equity grant, she directly holds 3,011 shares of Repligen common stock. The 995 restricted stock units and 2,239 stock options represent additional contingent or derivative interests that may convert into common shares upon vesting and, for options, future exercise at the set price.

When do Margaret Pax’s Repligen (RGEN) restricted stock units and options vest?

Both the 995 restricted stock units and the 2,239-share stock option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual shareholder meeting, which had not yet been determined at the time of the grant.